National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Appendix 16: Mycobacterium tuberculosis." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
252
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are approximately 23,000 new cases of mycobacterium tuberculosis (TB) in the United States each year. It was assumed that incidence of TB infection increases with age. It is assumed that half the cases occur in people belonging to a high-risk group and half occur in people in multi-drug resistant areas. It was estimated that there are approximately 1,500 deaths associated with TB annually. See Table A16–1.

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that most cases of TB infection result in pulmonary disease. Extrapulmonary disease is seen in the remaining 12% of infected people. The health utility index (HUI) was assumed to range from 1.0 for treatment of asymptomatic people (described below) to .89 for the 9-month treatment phase for pulmonary TB and .72 for 20 days of severe extrapulmonary TB (including hospitalization). See Table A16–2.

COST INCURRED BY DISEASE

Table 16–3 summarizes the health care costs incurred by TB infections. For the purposes of the calculations in this report, it was assumed that costs are incurred for both active and asymptomatic (suspected and latent) cases of TB. It is assumed that for every case of confirmed, active TB disease, treatment for 3 to 5 asymptomatic (suspected or latent) cases of TB is required until TB infection is confirmed. Asymptomatic, latent infections require additional treatment. These treatments are assumed to include two visits to a general physician, three visits to a nurse, diagnostic evaluation, and medications. Although the model assumes that all suspected cases of TB undergo the care described above, it is assumed that adherence to a 6-month treatment regime for latent infections is not complete (e.g., that 40% of patients take medications for only 3 months).

Health care costs incurred for pulmonary and extrapulmonary TB are assumed to involve hospitalization followed by 9 months of outpatient treatment. This follow-up involves monthly costs for a physician visit, diagnostic evaluation, and medication.

Page
252
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)